Tejal Somvanshi
**For Years, Doctors Couldn’t Give Clear Answers—Now Two New Studies Provide Clarity**
Evidence for statin primary prevention in healthy adults over 70 has been more limited than in younger populations. A landmark clinical trial released this week goes a long way toward providing data on that specific question.
A massive study called STAREE, conducted across Australia and led by researchers at Monash University, tracked nearly 10,000 people aged 70 and older for almost six years. These participants didn’t have existing heart disease, diabetes, or dementia. Researchers gave half of them atorvastatin (a common statin medication) at a 40-milligram dose. The other half received placebo.
The key finding: statin therapy was associated with a 30% relative reduction in major cardiovascular events. That means heart attacks, strokes, and procedures to unblock arteries were 30% less common in the statin group. Specifically, 6.0% of the statin group experienced a major cardiovascular event compared to 8.3% of the placebo group.
But here’s what the same study did not show: statin therapy did not significantly extend overall lifespan or improve what doctors call “disability-free survival”—living longer without dementia or physical disability. That matters because many people assume cardiovascular protection automatically means living longer, healthier lives overall. It doesn’t necessarily.
Why? About 80% of deaths recorded in the STAREE trial were from non-cardiovascular causes—cancer, respiratory illness, infections, and other conditions. A medication that prevents heart attacks doesn’t address those other causes. So while cardiovascular events decreased, total deaths remained similar between groups.
The safety profile was balanced. Serious adverse events occurred in 2.7% of both the statin and placebo groups. Muscle, liver and diabetes-related adverse events were more frequent in the atorvastatin group, while serious adverse events occurred in 2.7% of both groups.
A separate study conducted in Denmark provides a different piece of the puzzle. Researchers analyzed over 132,000 people who developed type 2 diabetes between 2006 and 2019. Those who started statins relatively early after diabetes diagnosis showed approximately 15% lower dementia risk over a decade. Those who started statins later showed about 10% lower dementia risk.
That’s interesting but comes with an important caveat: this was observational research, not a randomized controlled trial. Observational research documents associations—people who take statins had lower dementia rates—but doesn’t prove cause and effect. People who start statins early might also exercise more, eat better, or have other healthy habits that independently reduce dementia risk.
So what’s the actual answer to “should I start a statin”?
The evidence now says: if you’re over 70, don’t have established heart disease, and your doctor evaluates your cardiovascular risk, the randomized STAREE trial found that atorvastatin reduced major cardiovascular events in the studied population. However, don’t expect statins to extend your overall lifespan or guarantee you’ll avoid dementia.
For people with type 2 diabetes, starting statins earlier rather than later shows statistical association with lower dementia risk, but the evidence is less certain about causation.
Important: people shouldn’t start, stop, or change statin treatment based solely on news headlines. The STAREE study included people with specific characteristics—aged 70 and older without existing cardiovascular disease or diabetes. The Danish research involved people with type 2 diabetes. Your individual situation matters enormously.
Cardiovascular risk varies. Some people over 70 have lifestyle and genetic factors that put them at high risk for heart attack or stroke. Others have lower risk. Some have kidney disease or liver conditions that affect medication tolerance. A doctor evaluates all these factors before recommending statins.
Lead researcher Sophia Zoungas noted the findings provide reassurance about cardiovascular protection in older populations and expressed hope that treatment guidelines might be updated based on the evidence.
The takeaway: for the specific question “do statins help prevent heart attacks in older adults,” the STAREE trial provides evidence from a rigorous clinical study. For broader questions about living longer or preventing dementia, the evidence is more complex and requires individual medical evaluation.
